ethical issues
DESCRIPTION
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s P rogrammes at the University of Pécs and at the University of Debrecen Identification number : TÁMOP-4.1.2-08/1/A-2009-0011. - PowerPoint PPT PresentationTRANSCRIPT
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
ETHICAL ISSUES
Dr. Judit PongráczThree dimensional tissue cultures and tissue engineering – Lecture 27
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
TÁMOP-4.1.2-08/1/A-2009-0011
No ethical issues raised• Autologous cells• No life threatening conditions
TÁMOP-4.1.2-08/1/A-2009-0011
More ethical questions• Advanced human tissue engineering
therapies may also be used for life-threatening conditions
• Embryonic stem cells• Xenogeneic cells
TÁMOP-4.1.2-08/1/A-2009-0011
Regulation in Europe• Best regulated at European level• European framework laws• Directives adopted by the European
Commission and the European Parliament must be incorporated in national law
TÁMOP-4.1.2-08/1/A-2009-0011
The most relevant documents• Charter of Fundamental Rights of the EU• Convention on Biomedicine
TÁMOP-4.1.2-08/1/A-2009-0011
Ruling in 2011A single cell from an embryo can be considered as a human being.
TÁMOP-4.1.2-08/1/A-2009-0011
USA• Embryonic stem cells cannot be used• Only established cell lines can be used in
research• Adult stem cells can be applied in research
ECONOMIC SIGNIFICANCE
Dr. Judit PongráczThree dimensional tissue cultures and tissue engineering – Lecture 28
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
TÁMOP-4.1.2-08/1/A-2009-0011
Biotechnology • Medical• Pharmaceutical• Agricultural, etc
TÁMOP-4.1.2-08/1/A-2009-0011
Significance in the US• In 2001, 3,300 scientists and support staff
worked in tissue engineering alone• Over 70 start-up companies• Investment of 3.5 billion US dollars
TÁMOP-4.1.2-08/1/A-2009-0011
Significance in the EU• Fast growing• STILL• No venture capital in Europe
TÁMOP-4.1.2-08/1/A-2009-0011
Big Pharma• Refocusing to cell based therapies• Novel therapeutic approaches just in
treatment of diabetic patients alone